Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 13/20 | 0.34 |
| ▸ | TAB1 | Q15750 | 13/20 | 0.34 |
| ▸ | LPL | P06858 | 2/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30445860 | 1.00 | MAP3K7 (0.34) | MAP3K7TAB1LPLLIPGCYP2A6 | |
| SCHEMBL15574699 | 0.88 | CYP2A6 (0.41) | LPLLIPGCYP2A6 | |
| SCHEMBL574089 | 0.78 | MAPT (0.41) | LPLLIPGCYP2A6 | |
| SCHEMBL21412683 | 0.75 | — | — | |
| SCHEMBL658403 | 0.74 | EGFR (0.30) | — | |
| SCHEMBL657672 | 0.74 | LPL (0.30) | LPLLIPG | |
| SCHEMBL25027588 | 0.73 | LPL (0.41) | LPLLIPG | |
| SCHEMBL660756 | 0.72 | LATS1 (0.34) | — | |
| SCHEMBL660165 | 0.72 | LPL (0.31) | LPLLIPG | |
| SCHEMBL660193 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| WO-2024059524-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20220289712-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2022-09-15 | — | — | US | disclosed |
| CN-114341127-A | Aminopyrazine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2021032148-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021027594-A1 | IMIDAZOLOPYRIMIDINE COMPOUNDS COMPRISING FUSED RING GROUP, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2021-02-18 | — | — | WO | disclosed |
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2534156-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| WO-2011100502-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | MAP3K7 5/4885TAB1 4/4885LPL 4866/4885 |
| US-20220289712-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | MAPKAPK5, STK25, STK35 | MAP3K7 90/4885TAB1 563/4885LPL 2329/4885 |
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | MAP3K7 3720/4885TAB1 1882/4885LPL 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.